Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that CD30 + status confers therapeutic sensitivity to Brentuximab Vedotin in patients with Hodgkin Lymphoma.
The European Medicines Agency (EMA) has authorized brentuximab vedotin for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL) either following autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.
This statement is based on a regulatory approval from the European Medicines Agency:
ADCETRIS is indicated for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL): (i) following ASCT, or (ii) following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.